Search
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].
Categories: Agents for Dermatitis, Excluding CorticosteroidsCarbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnThe compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.
Categories: Compounds used in a research, industrial, or household settingRitonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalRitonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].[L40094] … Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or … produces proteins unresponsive to ivacaftor or tezacaftor.
Calcium glubionate anhydrous
go.drugbank.com/drugs/DB13142ApprovedCalcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Isopropamide
go.drugbank.com/drugs/DB01625ApprovedVet approvedWithdrawnIt is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Mixtures: Stelabid No 2, Stelabid No 1Categories: Drugs for Functional Gastrointestinal DisordersBaclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigationalAlthough originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
Products: Co Baclofen Tablets 10mg, Co Baclofen Tablets 20mgLutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigationalIt consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. … [L41290] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended lutetium Lu-177 vipivotide tetraxetan be granted marketing authorization for the treatment of prostate
Categories: Compounds used in a research, industrial, or household settingNateglinide
go.drugbank.com/drugs/DB00731ApprovedOne minor metabolite, the isoprene, has the same potency as its parent compound. … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[L44096] In April 2026, the FDA approved an expanded indication for teplizumab, lowering the eligible age range from 8 years and older down to 1 year and older for patients with Stage 2 T1D.[L56140] … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients